Mergers & AcquisitionsMedium•16 November 2026•
1 min read
Johnson & Johnson to Acquire Ollin Biosciences in $2.2 Billion Deal
Key Facts
1Johnson & Johnson has struck a $2.2 billion deal to acquire Ollin Biosciences, a biotech firm focused on eye diseases.
Johnson & Johnson has struck a $2.2 billion deal to acquire Ollin Biosciences, a biotech firm focused on eye diseases. investing.com reported that the definitive agreement aims to bolster the healthcare giant's ophthalmology portfolio by integrating specialized therapeutic pipelines.
JNJ closed at $285.75 on November 13, 2026, prior to the announcement of the acquisition. The transaction represents a strategic expansion into high-value therapeutic areas as Johnson & Johnson seeks to leverage Ollin Biosciences' specialized biotechnology assets.